




Pacific Center for
Emerging Infectious Diseases
Research



UNIVERSITY
of HAWAII
MĀNOA

Department of Tropical Medicine, Medical Microbiology & Pharmacology

JOHN A BURNS SCHOOL OF MEDICINE, UNIVERSITY OF HAWAII AT MANOA



LASER ART

Advances in the development of long acting antiretroviral therapy (ART) can revolutionize current treatments for HIV/AIDS. We have coined the term long active slow effective release ART (LASER ART) based on properties of slow drug dissolution, poor water-solubility, excellent bioavailability, limited off target systemic toxicities, and excellent patient treatment adherence. Drug carrier technologies characterized by high payload of antiretroviral drugs (ARVs) in a single carrier are being developed to improve the pharmacokinetics and pharmacodynamics of the nanoformulated ART (nanoART). Additionally, surface modification of slow release antiretroviral carriers with targeting ligands has facilitated receptor-mediated transport across physiological barriers serves to improve therapeutic outcomes. The lecture will discuss the future of ART where LASER ART treatments can be given once every few months and target hidden sites of sustained viral growth.

Howard E. Gendelman, M.D.

*Margaret R. Larson Professor of Infectious Diseases and Internal Medicine
Professor and Chair, Department of Pharmacology & Experimental Neuroscience
Editor-in-Chief, the Journal of Neuroimmune Pharmacology
University of Nebraska Medical Center
Omaha, Nebraska*

Thursday, March 2, 2017 at 9:00 a.m.
John A. Burns School of Medicine, Kaka'ako Campus
Medical Education Building Auditorium (Room 315)
For further information, contact (808) 692-1654

This seminar is supported by grant P30GM114737 (COBRE) from the National Institutes of Health.

